|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Blockers of IL-12/23, as well as specific blockers of IL-23, have been investigated as options for medical therapy in inflammatory bowel disease.
|
30571147 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunologically, type 3 immunity, especially interleukin (IL)-17 and IL-23 dysregulation, has been shown to play a central role in IBD, PsO and SpA.
|
30407224 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, it is lack of depth in whether TGP regulate T helper 17 cell (Th17) / T regulatory cell (Treg) immune balance or interleukin 23 (IL-23) / IL-17 axis to achieve the goal of treating IBD.
|
30612460 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review discusses the current state of IL-12/23 and IL-23 antagonists for the treatment of IBD.
|
30884245 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings underline the crucial regulatory role of IL-23 in chronic intestinal inflammation and colitis-associated cancer and indicate that therapeutic strategies aiming at IL-23 blockade may be of key relevance for future therapy of IBD patients.
|
30563755 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genes known to activate NF-κβ, such as, Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and Interleukin 23 (IL-23), are associated with IBD.
|
30425977 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Experimental colitis studies, including T cell-mediated colitis, indicate that IL-23 rather than IL-12 orchestrates intestinal inflammation in inflammatory bowel disease (IBD).
|
29391156 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-23/IL-17 axis significantly inhibited the development of inflammatory bowel disease.
|
30214568 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting IL-23, may be responsible for the high efficacy and durable responses of guselkumab, avoiding some adverse effects of IL-17A blockade, like mucocutaneous candida infections or triggering/worsening of inflammatory bowel disease, experienced with agents acting selectively against this molecule and that seem to be class related.
|
29897790 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin (IL)-12 and IL-23 that share subunit p40 are important cytokines in the pathogenesis of inflammatory bowel disease.
|
29788053 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The IL-23-driven tissue-resident group 3 innate lymphoid cells (ILC3s) play essential roles in intestinal immunity, and targeting IL-23/12 is a promising approach in IBD therapy.
|
28433688 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review will describe recent developments leading to the current understanding of the key role of IL-23 as a 'master regulator' of autoimmune inflammation and the clinical evidence for agents that specifically target this modulator in the context of treating psoriasis, spondyloarthropathy and inflammatory bowel disease.
|
29438576 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These Th9 conditions may explain the successful treatment against Inflammatory Bowel Disease (IBD) both with antibodies against IL-23 or through parasitization with nematodes.
|
29773890 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in the Interleukin (IL)-23/IL-23 receptor loci are associated with increased inflammatory bowel disease (IBD) susceptibility, and IL-23 neutralization has shown efficacy in early clinical trials.
|
28792532 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.
|
28573876 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This study was aimed to investigate the role of IL-6, IL-23 and its association with Treg and Th17 subsets in pediatric IBD patients.
|
29441874 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We report the development of safe lactic acid bacterium Lb. salivarius with the ability to simultaneously bind IL-17A, IL-23 and TNFα that could be administered orally for the treatment of IBD.
|
28190384 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, we found higher serum levels of IL-23 (p=0.008), TGFβ1 and IL-6 in IBD patients compared to non-IBD patients.
|
28088612 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.
|
27817215 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data thus indicated that the HMGB1-TLR2/4-DCs-IL-23 cascade pathway enhances the functions of ILC3s to produce IL-17 and IL-22, and this signal way might play a vital role in the development of IBD.
|
27670944 |
2016 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort.
|
26698117 |
2015 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The IL-17/IL-23 axis is relevant in IBD pathogenesis both in human and experimental studies.
|
26019446 |
2015 |
|
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Serum IL-17C levels are modified by IL23R genotypes and IL-17C mRNA correlates (r>0.5, P<0.001) with IL-17A, tumor necrosis factor (TNF)-α, C-C motif chemokine ligand 20 (CCL20) and IL-23 mRNA in the inflamed colon of IBD patients.
|
25492478 |
2015 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
All eight TYK2-deficient patients displayed impaired but not abolished cellular responses to (a) IL-12 and IFN-α/β, accounting for mycobacterial and viral infections, respectively; (b) IL-23, with normal proportions of circulating IL-17(+) T cells, accounting for their apparent lack of mucocutaneous candidiasis; and (c) IL-10, with no overt clinical consequences, including a lack of inflammatory bowel disease.
|
26304966 |
2015 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The subunit of IL-23 (IL12B) and its receptor (IL23R) gene single-nucleotide polymorphisms (SNPs) have been shown to be associated with several autoimmune diseases such as inflammatory bowel disease, psoriasis and ankylosing spondylitis.
|
24547735 |
2014 |